echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The new drug for dry eye has been filed for listing in the United States!

    The new drug for dry eye has been filed for listing in the United States!

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9, Novaliq announced that it has submitted a New Drug Application (NDA) to the FDA for CyclASol® (0.


    SHR8028 eye drops is an anti-inflammatory and immunomodulatory agent, oil-free, surfactant-free, paraben-free, with high topical bioavailability, reduction of blurred vision caused by oil-based eye drops, and improved ocular surface comfort degree advantage


    In November 2019, Hengrui reached an agreement from Novaliq GmbH in Germany to introduce the exclusive rights for the clinical development, production and marketing of dry eye drugs CyclASol and NOV03 (perfluorohexyloctane) in China, with a total sales of up to 165 million dollars


    In December 2021, Novaliq announced positive results from a pivotal Phase III clinical trial (ESSENCE-2) of CyclASol in dry eye disease


    Dry eye syndrome, also known as keratoconjunctiva xerophthalmia, is a general term for a group of diseases that cause dryness of the ocular surface epithelium due to low tear secretion or other causes of abnormal tear film.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.